Led by founder David Elmaleh, Ph.D., a renowned and prolific inventor and molecular scientist, the AZTherapies team shares a practical, innovative, entrepreneurial, and mission-driven approach to bringing therapeutics to patients more quickly, safely, and affordably.
Advancing a growing pipeline of candidates to treat patients with few therapeutic options, our lead program, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of disease. Our Phase 3 COGNITE trial in early Alzheimer’s disease is now fully enrolled and expected to complete in late 2020. Following our lead program, we are advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other neurodegenerative diseases.
AZTherapies is a private company headquartered in Boston, Massachusetts.
AZTherapies At A Glance
Leadership
Board of Directors
SCIENTIFIC FOUNDER, CHAIRMAN, AND CHIEF SCIENTIFIC OFFICER
CHIEF EXECUTIVE OFFICER
Scientific Advisors
CHAIR